Discontinue treatment at 1st appearance of signs & symptoms of severe skin reactions, eg, skin rash, mucosal lesions, or any other sign of hypersensitivity. Immediately discontinue treatment if acute intolerance reactions eg, abdominal cramps, acute abdominal pain, fever, severe headache & rash occurs. Severe cutaneous adverse reactions eg, SJS, TEN. Carefully monitor patients w/ pulmonary disease, particularly asthma. Patients w/ history of adverse drug reactions to sulphasalazine-containing prep; who have undergone bowel resection/surgery in ileocoecal region w/ removal of ileocoecal valve. Cases of nephrolithiasis. Determine blood tests (differential blood count, liver function parameters eg, ALT or AST, serum creatinine) & urinary status should be determined prior to & during treatment. Recommended follow-up tests 14 days after commencement of treatment, then further 2-3 tests at 4-wk interval. Follow-up tests should be carried out every 3 mth in normal findings. Immediately perform tests if additional symptoms occur. Ensure adequate fluid intake during treatment. Hepatic impairment. Not to be used in patients w/ impaired renal function. Pregnancy. Discontinue breastfeeding if infant develops diarrhoea.
Sign Out
